Tibet Rhodiola Pharm (600211.SS) traded flat 0 % during a 24 hours period ending at 01:11 PM Central Europe on Tuesday 27th. One Tibet Rhodiola Pharm stock can currently be bought for about CNY 36.01 on popular exchanges. Current supply of Tibet Rhodiola Pharm stocks is 322.3 mn. Tibet Rhodiola Pharm has a current market capitalization of CNY 11.8 bn and approximately CNY 89.8 mn worth of Tibet Rhodiola Pharm was traded on exchanges in the last 24 hours. Since last month end, Tibet Rhodiola Pharm has traded 1.78 % up. Simple moving average of last 200 days is at CNY 37.75. The highest price of past 52 weeks was recorded at CNY 48.99 on 11/14/2025. 52 weeks low was at CNY 34.8 on 06/29/2026.

Here is how related stocks have performed in the past 24 hours:

  • Jiangsu Shemar Electric (603530.SS) traded flat 0 % and now trades at CNY 32.01. Jiangsu Shemar Electric has a market capitalisation of CNY 14.1 bn. Jiangsu Shemar Electric has a current price to earnings ratio of 37.47.

  • Country Garden Services Hold (6098.HK) traded up 1.31 % and now trades at HKD 4.92. Country Garden Services Hold has a market capitalisation of HKD 16.5 bn. Country Garden Services Hold has a current price to earnings ratio of 25.45.

  • Xinjiang Joinworld (600888.SS) traded flat 0 % and now trades at CNY 8.9. Current market capitalisation for Xinjiang Joinworld is CNY 14 bn. Current price/earnings ratio for Xinjiang Joinworld is 16.54.

  • Shanghai Gentech (688596.SS) traded flat 0 % and now trades at CNY 40.47. Current market capitalisation for Shanghai Gentech is CNY 14.1 bn.

  • Shenzhen Kangtai Biologica (300601.SZ) traded flat 0 % and now trades at CNY 12.58. Current market capitalisation for Shenzhen Kangtai Biologica is CNY 14.2 bn. Shenzhen Kangtai Biologica has a current price to earnings ratio of 160.35. Shenzhen Kangtai Biologica reported a strong third‑quarter earnings release on 26 October. The company recorded a substantial rise in net profit, with the third‑quarter result growing more than double that of the second quarter and a full‑year increase approaching 94 %. Revenue for the quarter fell, but overseas operations showed a significant rebound, with sales in international markets up more than 140 % year‑over‑year. Management highlighted continued improvements in operating quality and a broadening of the product pipeline, noting new approvals and the expansion of multi‑valent and mRNA vaccine development. The company’s cash position remains solid and leverage ratios low, supporting its strategy of sustained research and global expansion. Recent institutional activity saw foreign and domestic public funds increase their holdings, signalling growing investor confidence.

About Tibet Rhodiola Pharm

Tibet Rhodiola Pharmaceutical Holding Co. is a health care provider and service company operating in the health care sector. The company, which has its base in Lhasa, China, specializes in developing, manufacturing, and marketing Tibet medicines. Their product range includes Rhodiola capsules, Rhodiola pellets, and other related medicines. You can find more information about their offerings on their website at www.xzyy.cn . They are listed on the Shanghai Stock Exchange. Their Initial Public Offering (IPO) date was July 1st, 1999.